Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Tivozanib> ?p ?o. }
Showing items 1 to 43 of
43
with 100 items per page.
- Tivozanib abstract "Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas. An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor. It was developed by AVEO Pharmaceuticals. It is designed to inhibit all three VEGF receptors.Phase III results on advanced renal cell carcinoma suggest a 30% or 3 months improvement in median PFS compared to sorafenib. The Food and Drug Administration's Oncologic Drugs Advisory Committee voted in May 2013 13 to 1 against recommending approval of tivozanib for renal cell carcinoma. The committee felt the drug failed to show a favorable risk-benefit ratio and questioned the equipose of the trial design, which allowed control arm patients who used sorafenib to transition to tivozanib following progression disease but not those on the experimental arm using tivozanib to transition to sorafenib. There was an inferior overall survival rate of the experimental arm versus the control arm in this Phase III study as well. The application was formally rejected by the FDA in June 2013, saying that approval would require additional clinical studies.".
- Tivozanib fdaUniiCode "172030934T".
- Tivozanib iupacName "1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea".
- Tivozanib thumbnail Tivozanib.svg?width=300.
- Tivozanib wikiPageID "27723967".
- Tivozanib wikiPageRevisionID "574761986".
- Tivozanib hasPhotoCollection Tivozanib.
- Tivozanib imagefile "Tivozanib.svg".
- Tivozanib imagesize "200".
- Tivozanib iupacname "1".
- Tivozanib othernames "AV-951".
- Tivozanib unii "1.72030934E8".
- Tivozanib subject Category:Angiogenesis_inhibitors.
- Tivozanib subject Category:Experimental_cancer_drugs.
- Tivozanib subject Category:Isoxazoles.
- Tivozanib subject Category:Quinolines.
- Tivozanib subject Category:Receptor_tyrosine_kinase_inhibitors.
- Tivozanib type Agent114778436.
- Tivozanib type AngiogenesisInhibitor102711422.
- Tivozanib type AngiogenesisInhibitors.
- Tivozanib type CausalAgent100007347.
- Tivozanib type Drug103247620.
- Tivozanib type Matter100020827.
- Tivozanib type Medicine103740161.
- Tivozanib type PhysicalEntity100001930.
- Tivozanib type ReceptorTyrosineKinaseInhibitors.
- Tivozanib type Substance100020090.
- Tivozanib type TyrosineKinaseInhibitor104506005.
- Tivozanib type ChemicalCompound.
- Tivozanib type ChemicalSubstance.
- Tivozanib type ChemicalObject.
- Tivozanib type Thing.
- Tivozanib comment "Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas. An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor. It was developed by AVEO Pharmaceuticals.".
- Tivozanib label "Tivozanib".
- Tivozanib label "Tivozanib".
- Tivozanib sameAs Tivozanib.
- Tivozanib sameAs m.0cc8_6z.
- Tivozanib sameAs Q7810457.
- Tivozanib sameAs Q7810457.
- Tivozanib sameAs Tivozanib.
- Tivozanib wasDerivedFrom Tivozanib?oldid=574761986.
- Tivozanib depiction Tivozanib.svg.
- Tivozanib isPrimaryTopicOf Tivozanib.